FY2026 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Analysts at Leerink Partnrs raised their FY2026 earnings per share estimates for REGENXBIO in a research report issued on Tuesday, May 27th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($1.65) per share for the year, up from their prior forecast of ($1.69). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's FY2027 earnings at ($3.16) EPS, FY2028 earnings at ($2.59) EPS and FY2029 earnings at ($1.76) EPS.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The firm had revenue of $89.01 million for the quarter, compared to analyst estimates of $105.35 million.

Other analysts have also recently issued reports about the company. Leerink Partners set a $24.00 price objective on REGENXBIO in a research note on Tuesday, March 18th. HC Wainwright reduced their price objective on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, March 17th. Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Thursday, March 20th. Wall Street Zen upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Finally, Morgan Stanley increased their price objective on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, REGENXBIO currently has an average rating of "Moderate Buy" and an average price target of $31.63.

REGENXBIO Stock Up 0.4%

NASDAQ:RGNX traded up $0.04 during trading hours on Friday, reaching $10.39. 412,981 shares of the stock were exchanged, compared to its average volume of 1,057,715. The business has a 50-day moving average of $7.93 and a two-hundred day moving average of $7.92. REGENXBIO has a twelve month low of $5.03 and a twelve month high of $15.36. The company has a market capitalization of $521.16 million, a price-to-earnings ratio of -2.07 and a beta of 1.11.

Hedge Funds Weigh In On REGENXBIO

Hedge funds have recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new position in shares of REGENXBIO during the first quarter worth about $35,000. Brooklyn Investment Group grew its holdings in shares of REGENXBIO by 163.7% during the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 3,466 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of REGENXBIO during the fourth quarter worth about $54,000. Pallas Capital Advisors LLC purchased a new position in shares of REGENXBIO during the first quarter worth about $74,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of REGENXBIO during the fourth quarter worth about $79,000. Hedge funds and other institutional investors own 88.08% of the company's stock.

Insider Buying and Selling at REGENXBIO

In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of the firm's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $7.91, for a total transaction of $162,961.82. Following the transaction, the director now owns 475,103 shares of the company's stock, valued at approximately $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 12.79% of the stock is owned by insiders.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.